Guide · 8 min
Beyond Antihistamines: The New Wave of Hayfever Treatments Worth Knowing About
From light therapy to smarter immunotherapy — what the emerging science actually says
In short
Intranasal phototherapy using red and near-infrared light (photobiomodulation therapy) demonstrates clinically meaningful reductions in core allergic rhinitis symptoms—rhinorrhea, sneezing, nasal pruritus, and obstruction—with large effect sizes reported in a 2022 meta-analysis…
When the usual tools aren't enough
If you've ever stood in a pharmacy aisle staring at rows of antihistamines, wondering whether there's something — anything — that might work better, you're not alone. For millions of people, first-line hayfever treatments manage symptoms without ever quite silencing them. The runny nose still arrives. The sneezing still disrupts the meeting. The fogginess still follows.
The good news: science hasn't stopped at cetirizine. Across laboratories, clinics, and trial centres, researchers are quietly building a body of evidence for approaches that work very differently from anything in that pharmacy aisle. Some are centuries old, revisited with modern rigor. Others are cutting-edge molecular medicine. None are perfect yet — but all are genuinely interesting, and some are already accessible to you.
Here's what the current evidence actually shows.
The science
Shining a light — literally
It sounds almost implausibly simple: point a small device emitting red or near-infrared light into your nostrils for a few minutes each day, and your hayfever symptoms improve. Yet this is exactly what a growing body of evidence suggests.
The mechanism is rooted in cell biology. Red and near-infrared photons are absorbed by mitochondrial proteins — particularly an enzyme called cytochrome c oxidase — triggering a cascade of anti-inflammatory effects. These include the suppression of IgE and IL-4 (key drivers of the allergic response), inhibition of mast cell histamine release, and the promotion of healthier nasal mucosal tissue (Koreck et al., 2005).
The clinical evidence has been accumulating since 1997, when Neuman and Finkelstein published early work on narrow-band red light in perennial allergic rhinitis. A 2020 meta-analysis by Kang et al. synthesised available trial data and found effect sizes ranging from -1.10 to -1.35 across core symptoms — rhinorrhea, sneezing, nasal pruritus, and obstruction — which, in research terms, counts as a large effect. More recently, a 2025 double-blind RCT by Oliveira et al. (n=62) confirmed significant improvements in peak nasal inspiratory flow and rhinitis control scores versus sham treatment.
Importantly, this therapy — formally called photobiomodulation therapy (PBMT) — appears particularly promising for perennial allergic rhinitis, where the nasal turbinates have undergone more sustained inflammatory changes. Whether the same magnitude of benefit applies to purely seasonal hayfever is less clear.
Physical barriers: a surprisingly robust idea
Nasal filters are precisely what they sound like — small, discreet devices worn in the nostrils that physically intercept pollen before it reaches the nasal mucosa. No drugs, no side effects, no systemic involvement. Just mechanics.
A double-blind RCT by Kenney et al. (2015) found a 40% median reduction in Total Nasal Symptom Scores with nasal filter use during natural pollen exposure. Sneezing dropped by 83%, and runny nose by 53% compared to placebo. A 2020 systematic review and meta-analysis broadly supports these findings across barrier devices.
Newer hybrid designs combine mechanical filtration with chemical adhesion via blocking gels, with experimental studies reporting near-complete pollen capture in laboratory conditions (Zhang et al., 2025). These haven't yet been validated in real-world clinical settings, but the direction of travel is encouraging.
Acupuncture: more evidence than you might expect
Acupuncture is often dismissed as belonging to a different category of medicine entirely. The evidence, while imperfect, deserves a more nuanced reading.
A 2022 meta-analysis by He et al. pooled data from 30 RCTs (n=4,413) and found statistically significant improvements in nasal symptom scores and quality of life versus sham acupuncture or no treatment. The proposed mechanisms include downregulation of IgE-mediated inflammatory pathways, suppression of mast cell degranulation, and possible neurological modulation via changes in prefrontal cortex connectivity (Feng et al., 2015).
The honest caveat: most of this research focuses on perennial rather than seasonal allergic rhinitis. A 2015 RCT by Xue et al. specifically examined seasonal AR and found positive results, but it remains one of relatively few studies to isolate hayfever as the target condition.
Omalizumab: precision medicine for severe cases
For those at the more severe end of the spectrum — particularly where hayfever coexists with asthma — anti-IgE biologics represent a genuinely different class of intervention.
Omalizumab works upstream of the entire allergic cascade. It binds to free circulating IgE in the bloodstream, preventing it from attaching to mast cells and basophils. Without that attachment, the allergen-triggered explosion of histamine and Th2 cytokines (IL-4, IL-5, IL-13) that drives nasal inflammation simply can't occur in the same way (Pfaar et al., 2021).
A 2021 systematic review by Tsabouri et al. and a 2019 meta-analysis by Yu et al. both confirm meaningful reductions in total nasal symptom scores, improved quality of life, and reduced rescue medication use compared to placebo. Real-world data across diverse patient populations — including those with comorbid asthma — corroborate the trial findings. The safety profile, across multiple trials, appears favorable.
The important context: omalizumab is not a treatment you pick up at a pharmacy. It requires specialist referral, subcutaneous injection, and carries significant cost. It currently lacks specific regulatory approval for allergic rhinitis in most countries, though it is approved for severe allergic asthma and is used off-label in rhinitis.
Novel immunotherapy routes: the frontier
Conventional allergen immunotherapy — the process of gradually desensitising your immune system to pollen — is the only treatment that can modify the underlying disease rather than just managing symptoms. But it traditionally requires three to five years of regular injections or daily sublingual drops.
Researchers are working hard to change that.
Intralymphatic immunotherapy (ILIT) delivers allergen directly into lymph nodes under ultrasound guidance, exploiting the high density of immune-priming cells there. Early trials suggest that just three injections over three months may achieve comparable desensitisation to years of conventional therapy (Hylander et al., 2013; von Moos et al., 2011).
Epicutaneous immunotherapy (EPIT) takes a different route, applying allergen via skin patches and using the skin's network of Langerhans cells to drive tolerogenic immune responses. Most EPIT evidence currently comes from food allergy research or preclinical models; pollen-specific trials are at an early stage.
Both approaches are genuinely exciting. Both are also genuinely early. Phase III trial data in seasonal hayfever specifically is still lacking for either route.
What this means for you
If your hayfever is mild-to-moderate and reasonably controlled, the emerging therapies reviewed here are probably not your first port of call — standard treatments remain better evidenced overall. But if antihistamines and nasal sprays aren't giving you adequate control, or if you're looking for drug-free adjuncts to your existing regimen, some of these options may be worth exploring.
Nasal filters are the most immediately accessible option: no prescription required, no systemic effects, and the evidence for symptom reduction during high-exposure moments (outdoor events, peak pollen days) is reasonably robust. Intranasal phototherapy devices are available consumer products in several markets; the evidence base, while not yet definitive, is more credible than many people realise.
Acupuncture — if you're open to it — has a more substantial evidence base than its reputation sometimes suggests, particularly for perennial rhinitis. For seasonal hayfever specifically, the evidence is thinner but not absent.
Omalizumab is a conversation to have with an allergy specialist if your symptoms are severe, poorly controlled, and particularly if asthma is also in the picture.
The evidence landscape: what we know and what we don't
It's important to be honest about confidence levels here. None of these emerging therapies has the same depth of evidence as intranasal corticosteroids, which remain the gold standard for moderate-to-severe allergic rhinitis.
Intranasal phototherapy has a consistent positive signal across nearly 30 years of research, but trials are uniformly small (the largest RCT has n=62), heterogeneity between studies is very high (I² >91%), and there are no head-to-head comparisons with standard pharmacotherapy. We genuinely don't know the optimal wavelength, dose, or session frequency.
Nasal filters have solid RCT evidence for symptom reduction during controlled exposure, but real-world adherence is poorly studied, and performance across different pollen types and concentrations hasn't been systematically characterised.
Acupuncture benefits from a relatively large pooled evidence base, but variable methodological quality, limited sham-control rigour, and the near-absence of hayfever-specific trials all temper confidence.
Omalizumab arguably has the strongest evidence of this group, but lacks regulatory approval for rhinitis in most countries, is expensive, and long-term data beyond six months are limited.
ILIT and EPIT are genuinely promising but genuinely early. Until Phase III trial data arrives, these remain investigational.
The honest summary: moderate confidence in omalizumab for severe cases, moderate confidence in nasal filters and phototherapy as adjunctive approaches, moderate confidence in acupuncture for perennial rhinitis, and low confidence in the novel immunotherapy routes for seasonal hayfever specifically.
What Haelo recommends
If you want a drug-free option for high-pollen days: Nasal filters are the most evidence-backed choice. Consider them for outdoor events, exercise, or the peak of your personal pollen season. They work best as part of a broader avoidance strategy rather than a standalone treatment.
If you're curious about phototherapy: Intranasal phototherapy devices are commercially available. The mechanism is credible, the evidence direction is positive, and the safety profile appears excellent. It's reasonable to try — just keep expectations calibrated to the current (limited) trial sizes, and treat it as an adjunct rather than a replacement for pharmacotherapy.
If you've tried acupuncture and found it helpful: The evidence supports continuing. If you haven't tried it and are interested in non-pharmacological options, the evidence base is more credible than you might assume — particularly if your rhinitis is year-round rather than purely seasonal.
If your symptoms are severe and poorly controlled: Ask your GP for an allergy specialist referral. Omalizumab may be an option, particularly if you have comorbid asthma. You may also be a candidate for conventional allergen immunotherapy, which remains the most evidence-backed disease-modifying treatment.
If you're interested in the future of immunotherapy: Watch this space. ILIT in particular looks promising as a compressed-protocol alternative to conventional desensitisation. The next two to three years of trial data will be telling.
Above all: track your symptoms carefully. Understanding your personal pollen triggers, peak exposure windows, and response to different interventions is the foundation of intelligent hayfever management — and it's what Haelo is built to help you do.
The evidence in this field is evolving. Haelo will update this article as new trial data emerges.
The evidence
What the research actually says
Each answer below is drawn from a graded research review. Confidence reflects the strength of the underlying evidence, not how confident we feel about it.
What is the evidence for intranasal phototherapy (red/near-infrared light) in allergic rhinitis?
Intranasal phototherapy using red and near-infrared light (photobiomodulation therapy) demonstrates clinically meaningful reductions in core allergic rhinitis symptoms—rhinorrhea, sneezing, nasal pruritus, and obstruction—with large effect sizes reported in a 2022 meta-analysis (ES ranging from -1.10 to -1.35) and significant improvements in peak nasal inspiratory flow and rhinitis control scores in a 2024 double-blind RCT (n=62). Evidence spans nearly three decades of study from 1997 to 2025, consistently showing superiority over sham/placebo controls with a favorable safety profile. However, the overall evidence base remains constrained by small sample sizes, high heterogeneity (I² >91%), and a lack of standardized treatment protocols across trials.
How it works
Red and near-infrared photons are absorbed by mitochondrial chromophores (particularly cytochrome c oxidase), triggering anti-inflammatory cascades that induce apoptosis of activated immune cells, suppress pro-inflammatory mediators including IgE and IL-4, inhibit mast cell histamine release, and promote mucosal remodeling in the nasal epithelium. These immunomodulatory effects are thought to be more pronounced in perennial allergic rhinitis where chronic inflammatory changes in the nasal turbinates provide a more sustained therapeutic target.
Confidence: moderate
How effective are nasal filters and barrier devices at reducing pollen inhalation?
Nasal filters and barrier devices demonstrate meaningful reductions in allergic rhinitis symptoms during pollen exposure, with a double-blind RCT reporting a 40% median reduction in Total Nasal Symptom Scores and marked reductions in individual symptoms such as sneezing (83%) and runny nose (53%) compared to placebo. A 2020 systematic review and meta-analysis supports these findings, indicating that barrier protection measures broadly improve AR symptom outcomes. Emerging devices such as bionic nasal hair/blocking gel masks show high experimental filtration efficiency (100% at 15 minutes), though these require validation in clinical settings.
How it works
Nasal filters and barrier devices physically intercept airborne pollen particles before they contact the nasal mucosa, preventing allergen binding to IgE-sensitized mast cells and the subsequent inflammatory cascade that drives rhinitis symptoms. Novel hybrid devices augment mechanical filtration with chemical adhesion via blocking gels, potentially improving capture efficiency across a wider range of particle sizes.
Confidence: moderate
What is the evidence for acupuncture in treating hayfever?
Multiple systematic reviews and meta-analyses indicate that acupuncture produces statistically significant improvements in nasal symptom scores and quality of life in allergic rhinitis patients compared to sham acupuncture or no treatment, with the 2022 meta-analysis of 30 RCTs (n=4413) providing the most robust pooled evidence to date. However, evidence specific to seasonal allergic rhinitis (hayfever) remains limited, as most trials focus on perennial allergic rhinitis, and methodological quality across studies is variable. The overall direction of evidence is positive but not definitive, particularly for seasonal presentations.
How it works
Acupuncture is proposed to modulate immune responses by downregulating IgE-mediated inflammatory pathways, reducing pro-inflammatory cytokines, and suppressing mast cell degranulation in nasal mucosa, thereby decreasing nasal hyperreactivity. Neurological modulation via prefrontal and motor cortex functional connectivity may also contribute, though direct immunological mechanistic evidence in hayfever specifically remains preliminary.
Confidence: moderate
How effective are anti-IgE biologics (omalizumab) for severe allergic rhinitis?
Omalizumab demonstrates consistent clinical efficacy for severe and seasonal allergic rhinitis inadequately controlled by standard therapies, with multiple RCTs and meta-analyses showing significant reductions in total nasal symptom scores, improved rhinoconjunctivitis quality of life, and reduced rescue medication use compared to placebo plus standard-of-care. A 2021 systematic review and meta-analysis of RCTs (Tsabouri et al.) and a 2019 meta-analysis (Yu et al.) both confirm these benefits, and real-world data corroborate meaningful symptom relief across diverse patient populations including those with asthma comorbidity. The safety profile appears favorable with no unexpected adverse signals reported across trials.
How it works
Omalizumab binds circulating free IgE, preventing its attachment to high-affinity FcεRI receptors on mast cells, basophils, and dendritic cells, thereby blocking allergen-triggered degranulation, histamine release, and downstream Th2 cytokine production (IL-4, IL-5, IL-13) that drive nasal mucosal inflammation in AR. This interruption of the IgE-mediated inflammatory cascade attenuates both early- and late-phase nasal allergic responses in a dose-dependent manner.
Confidence: moderate
What novel immunotherapy approaches (epicutaneous, intralymphatic) are in clinical trials for hayfever?
Intralymphatic immunotherapy (ILIT) has demonstrated promising efficacy and safety for pollen-induced allergic rhinitis in several small-to-moderate RCTs, with a compressed dosing schedule of only 3 injections over 3 months compared to years of conventional subcutaneous immunotherapy (SCIT). Epicutaneous immunotherapy (EPIT) for hayfever remains largely investigational, with most evidence derived from preclinical work or food allergy models rather than completed pollen-specific trials. Both approaches are positioned as patient-friendly alternatives to SCIT, but robust Phase III data with direct SCIT comparisons for seasonal allergic rhinitis are still lacking.
How it works
ILIT delivers allergen directly into inguinal lymph nodes under ultrasound guidance, exploiting the high concentration of antigen-presenting cells and T-regulatory cell priming sites to induce tolerance more efficiently with far lower total allergen doses. EPIT leverages the skin's dense network of Langerhans cells and dermal dendritic cells, which are thought to preferentially drive tolerogenic rather than sensitizing immune responses upon epicutaneous allergen exposure.
Confidence: low
Where the evidence runs out
No adequately powered head-to-head RCTs comparing intranasal phototherapy directly to first-line pharmacological treatments (intranasal corticosteroids or oral antihistamines) exist, making it impossible to establish equivalence or superiority relative to standard of care. Critical unknowns include optimal wavelength combinations, session frequency, total dose parameters, durability of response beyond the treatment period, and whether efficacy differs meaningfully between seasonal and perennial phenotypes at the individual patient level. Direct head-to-head comparisons between nasal barrier devices and first-line pharmacotherapy (e.g., intranasal corticosteroids or antihistamines) are lacking, making it difficult to establish their relative place in clinical practice. Long-term adherence, real-world filtration performance across diverse pollen types and concentrations, and standardized efficacy metrics across device types remain insufficiently studied. High-quality RCTs isolating seasonal allergic rhinitis (hayfever) with robust sham controls, standardized allergen exposure models, and immunological biomarkers (e.g., IgE, nasal cytokines) are largely absent, limiting direct applicability to hayfever sufferers. Long-term follow-up data beyond 4 weeks and head-to-head comparisons with first-line pharmacological treatments such as intranasal corticosteroids are also lacking. Omalizumab currently lacks regulatory approval specifically for AR in most jurisdictions, and robust long-term data beyond 6 months, head-to-head comparisons with other biologics (e.g., dupilumab) or allergen immunotherapy, and adequate evidence in perennial AR and pediatric populations remain notably absent. Predictors of non-response and cost-effectiveness analyses are also insufficiently characterized to guide clinical selection criteria. No large Phase III RCTs have been completed for either ILIT or EPIT specifically targeting seasonal hayfever (grass or birch pollen), and no published head-to-head comparisons with SCIT report standardized symptom or quality-of-life outcome measures. Long-term durability of tolerance beyond the active treatment period, optimal dosing protocols, and comparative safety at scale remain unresolved for both routes.
References
- 1.Oliveira PC et al. · 2025 · Efficacy of Using Photobiomodulation Therapy in Allergic Rhinitis: A Placebo-Controlled Randomized Clinical Trial
- 2.Kang J et al. · 2020 · Effects and safety of intranasal phototherapy for allergic rhinitis
- 3.Neuman I, Finkelstein Y · 1997 · Narrow-band red light phototherapy in perennial allergic rhinitis and nasal polyposis
- 4.Kenney P et al. · 2015 · Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo-controlled crossover park study
- 5.Zhang Y et al. · 2025 · An experimental study on the pollen particle blocking efficacy of a barrier nasal mask
- 6.He M et al. · 2022 · Acupuncture for allergic rhinitis: a systematic review and meta-analysis
- 7.Xue C et al. · 2015 · Acupuncture for seasonal allergic rhinitis: a randomized controlled trial
- 8.Feng S et al. · 2015 · Acupuncture for the Treatment of Allergic Rhinitis: A Systematic Review and Meta-Analysis
- 9.Tsabouri S et al. · 2021 · Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis
- 10.Yu C et al. · 2019 · Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials
- 11.Pfaar O et al. · 2021 · Anti-IgE: A treatment option in allergic rhinitis?
- 12.Hylander T et al. · 2013 · Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis
- 13.Senti G, Kündig T · 2016 · Novel Delivery Routes for Allergy Immunotherapy: Intralymphatic, Epicutaneous, and Intradermal
This article is general information about hayfever, not medical advice. It should not replace guidance from your GP, pharmacist or allergy specialist — particularly if you are pregnant, treating a child, or managing asthma alongside hayfever. Read our medical disclaimer.
